nascobal (r) (b 12) demand is strong

Quote
ALERT

Astra Zeneca and Par launched a nationwide ad campaign that metoprolol is now in full supply. No competition and whopping price increase equals a nice quarter report and will par pre announce?


((((((((((((((((((((((((((((((((((((((((((((((((((((((((((PREANNOUNCE)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
 






THE P COMPANIES said:
ZAKS UPGRADE


Par Pharmaceutical Companies, Inc. (NYSE: PRX - News), the generic drug manufacturer, saw revenue grow 32% as sales popped for Metroprolol, the generic version of angina drug Toprol. The company's surprise of 81.48% had analysts scrambling to raise estimates. PRX is trading with a PEG ratio of just 0.79.

Company Description

Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States.

The branded division, Strativa Pharmaceuticals, was launched in 2005 and has licensed 4 proprietary drugs that are in development.

Revenue Surged 32% in the First Quarter

On May 6, Par reported first quarter results which easily surprised on Wall Street estimates by 81.48%. Adjusted earnings per share were 49 cents compared to 17 cents in the year ago period. Analysts were expecting just 27 cents.

Revenue grew 32% to $204 million from $154.9 million in the year ago period. Growth was fueled by a 127% increase in sales of Metroprolol, a generic version of Toprol XL, which treats angina.

Par became the authorized generic distributor for Toprol, which was developed by AstraZeneca, in the first quarter. Gains in three other generic drugs offset declines in fluticasone and Megace ES.

Consensus Estimates Jump

Given the far better-than-expected second quarter results, covering analysts have been raising estimates for the second quarter and the full-year.

Second-quarter consensus estimates rose 65% to 43 cents from 26 cents in the last 30 days with 7 out of 8 covering analysts raising during that time.

Full-year consensus estimates jumped 44% to $1.31 from 91 cents in the last month, also with 7 out of 8 analysts raising estimates.

Value Fundamentals

Par Pharmaceuticals is a Zacks #1 Rank (strong buy) stock. It has attractive value characteristics. Its forward P/E is 11.9 while its price-to-book is 1.09. Analysts expect 5-year earnings growth of 13%.


Related Quotes
Symbol Price Change
PRX 14.54 0.00


{"s" : "prx","k" : "c10,l10,p20,t10","o" : "","j" : ""} "PRX" Free Stock Analysis: Buy? Sell? Hold?

Zacks Investment Research
Click to expand...


zacks is my number 0ne source, NICE
 












Thin film market larger then expected!


THE P COMPANIES said:
View all Topics | View all Messages < Newer Topic | Older Topic >
Re: NEW INDICATION FOR PAR'S ODANSETRON 17 second(s) ago

glad to see pharma guy you finally agree the scientists are a better source and note this

“Getting off opioids can be tough, and we think there’s a better way to do it,” said Lawrence Chu, assistant professor of anesthesia at Stanford University’s School of Medicine in Palo Alto, California, in a telephone interview. “This is new evidence for a better way to treat this problem.”

the study is funded by the usa and yes par will benefit from the results determined by the scientists and funded by my tax dollars

with the advantages of the thin film , par will do quite well with odansetron




They are underestimating the market size for the thin film.


They are underestimating the market size for the thin film.

AND THE PRESS RELEASE YESTERDAY ON ODANSETRON INDICATED ACCELERATED APPROVAL BY ABOUT 3 - 6 MONTHS SUPERB NEWS INDEED FOR US LONGS


this is the best of both worlds as par gets the added patient population in effect and the study is rightly paid for by us tax payers

((((((((((((((($16 soon real soon)))))))))))))
Click to expand...
 






ALERT

LORAMYC submission by bioalliance on behalf of par just submitted to fda at this moment

And some estimates this would take 6 months were wrong as it took JUST 6 weeks


(((((((((((((((((((PRE ANNOUNCE))))))))))))))
 






Re: HI TECH ADDED TO RUSSELL BY 6/26


Add HI-TECH PHARMACAL CO INC HITK Health Care



Add HICKORY TECH CORP HTCO Utilities
Add HOME BANCORP INC HBCP



Is par on the russell rebalance listing?
 






Par competitor HITK is an addition which is very BULLISH but I defer to bosshog as a test to find the answer to your very appropriate and timely question

((((((((((((((((PAR TO PRE ANNOUNCE?))))))))))

((((((((((((((($16 SOON))))))))))
 


















Anonymous Posts: n/a

Re: nascobal (r) (b 12) demand is strong

--------------------------------------------------------------------------------

Re: HI TECH ADDED TO RUSSELL BY 6/26


Add HI-TECH PHARMACAL CO INC HITK Health Care



Add HICKORY TECH CORP HTCO Utilities
Add HOME BANCORP INC HBCP



Is par on the russell rebalance listing?


thanks for the great news
 






How did he know????

Re: LORAMYC Filing JUST ANNOUNCED 8 second(s) ago I TOLD YOU ABOUT THIS YESTERDAY

FOR THE SIMPLE MINDED LIKE DEMPSEY IE BOSSHOG THAT WAS ONE DAY EARLY

Loramyc(R) NDA
On Tuesday June 16, 2009, 9:25 am EDT
Buzz up! Print Related:par Pharmaceutical Companies Inc.
WOODCLIFF LAKE, N.J., June 16 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX - News), today announced that its development partner, BioAlliance Pharma, has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Loramyc® (miconazole Lauriad®) 50mg mucoadhesive buccal tablets, as planned. If approved, Strativa could launch Loramyc in the second half of 2010.

Related Quotes
Symbol Price Change
PRX 14.48 +0.07


{"s" : "prx","k" : "c10,l10,p20,t10","o" : "","j" : ""} Loramyc (miconazole Lauriad®), an innovative antifungal therapy for the treatment of oropharyngeal candidiasis, was approved in the European Union in 2007 and is currently marketed in several EU territories.



Sentiment : Strong Buy
Rating :
(No ratings) the_p_compa...




--------------------------------------------------------------------------------

View Messages

Report Abuse
 












and the big debate is whether to PRE ANNOUNCE

SHORTS WOULD GET THE FINAL KNIFE IN THEIR BACK


(((((((((((((((((((((((((((((PRE ANNOUNCE)))))))))))))))))))


I RAISED THE TARGET MORE FORTHCOMING
 












That's right a $$B buyout. To those of you still pushing ranbaxy, no way. While a foreign suitor makes the most sense, will it be by the big 3?

((((((((((((((((((((((((((PRE ANNOUNCE)))))))))))))))))
 






THE P COMPANIES said:
That's right a $$B buyout. To those of you still pushing ranbaxy, no way. While a foreign suitor makes the most sense, will it be by the big 3?

((((((((((((((((((((((((((PRE ANNOUNCE)))))))))))))))))
Click to expand...


and watson trades UP despite being the suitor which presages well for the par suitor!
Preannounce to juice up before the buyout
 












Anonymous said:
We are hearing buyout rumors again. Watch out. Watson just did arrow for 1.75b on 600m in annual sales. That makes par worth $2b. Someone stated that before???
Click to expand...

Arrow has a settlement with Pfizer to launch Lipitor in 2011. Arrow has a Global presence. P companies is a moron if he thinks the value of Par and Arrow are even in the same realm.
 






Thanks for asking

My calculation has $1.5b as an upper range. Remember that par has an extensive and impressive first to file portfolio and the branded division has nascobal and 2-3 compounds (one with expanded indications) set to hit the market in the next 15 months. Par's annual sales exceed arrow's as well as annual profits. Par continues to trade BELOW conservative book value.
As a result I have boosted my price targets by 20%.

(((((((((((((((((((((((((((((((((((((PRE ANNOUNCE)))))))))))))))))))))))))))))))))
 






THE P COMPANIES said:
Thanks for asking

My calculation has $1.5b as an upper range. Remember that par has an extensive and impressive first to file portfolio and the branded division has nascobal and 2-3 compounds (one with expanded indications) set to hit the market in the next 15 months. Par's annual sales exceed arrow's as well as annual profits. Par continues to trade BELOW conservative book value.
As a result I have boosted my price targets by 20%.

(((((((((((((((((((((((((((((((((((((PRE ANNOUNCE)))))))))))))))))))))))))))))))))
Click to expand...



HUGE
 






Top Bottom
Back
Quote